v3.26.1
Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)
12 Months Ended
Mar. 31, 2026
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
  

March 31,

 
  

2026

  

2025

 
         

Accrued compensation

 $593  $626 

Accrued clinical research costs

  275   134 

Accrued product development costs

  30   111 

Accrued professional fees

  38   52 

Accrued franchise tax

  50   50 

Accrued director fees

     46 

Other miscellaneous accrued expenses

  19   12 
         

Total accrued expenses

 $1,005  $1,031 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
  

March 31,

 
  

2026

  

2025

 
         

Equity based warrants to purchase common shares

  4,334   87,531 

Bridge financing warrants

  25,003   25,003 

Stock options granted

  13,500   243,483 

Series A warrants

  55,500   1,533,096 

Series B warrants

  1,477,596    

Series C warrants

  9,003,332    

Representative Warrants

  180,641   91,985 
         

Total potentially dilutive securities

  10,759,906   1,981,098